PH12015502282A1 - Alpha-2 adrenoceptor and sigma receptor ligand combinations - Google Patents
Alpha-2 adrenoceptor and sigma receptor ligand combinationsInfo
- Publication number
- PH12015502282A1 PH12015502282A1 PH12015502282A PH12015502282A PH12015502282A1 PH 12015502282 A1 PH12015502282 A1 PH 12015502282A1 PH 12015502282 A PH12015502282 A PH 12015502282A PH 12015502282 A PH12015502282 A PH 12015502282A PH 12015502282 A1 PH12015502282 A1 PH 12015502282A1
- Authority
- PH
- Philippines
- Prior art keywords
- alpha
- adrenoceptor
- receptor ligand
- sigma receptor
- ligand combinations
- Prior art date
Links
- 102000030484 alpha-2 Adrenergic Receptor Human genes 0.000 title 1
- 108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 title 1
- 239000003982 sigma receptor ligand Substances 0.000 title 1
- 239000013543 active substance Substances 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 239000000384 adrenergic alpha-2 receptor agonist Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13382140.5A EP2792352A1 (en) | 2013-04-16 | 2013-04-16 | Alpha-2 adrenoreceptor and sigma receptor ligand combinations |
| PCT/EP2014/057608 WO2014170319A1 (en) | 2013-04-16 | 2014-04-15 | Alpha-2 adrenoceptor and sigma receptor ligand combinations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12015502282A1 true PH12015502282A1 (en) | 2016-02-01 |
Family
ID=48227118
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12015502282A PH12015502282A1 (en) | 2013-04-16 | 2015-10-01 | Alpha-2 adrenoceptor and sigma receptor ligand combinations |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20160058771A1 (enExample) |
| EP (2) | EP2792352A1 (enExample) |
| JP (1) | JP2016516792A (enExample) |
| KR (1) | KR20150143754A (enExample) |
| CN (1) | CN105228606A (enExample) |
| AR (1) | AR095858A1 (enExample) |
| AU (1) | AU2014255837A1 (enExample) |
| BR (1) | BR112015026259A2 (enExample) |
| CA (1) | CA2908926A1 (enExample) |
| HK (1) | HK1219431A1 (enExample) |
| MX (1) | MX2015014441A (enExample) |
| PH (1) | PH12015502282A1 (enExample) |
| RU (1) | RU2015148766A (enExample) |
| SG (1) | SG11201508102XA (enExample) |
| TN (1) | TN2015000440A1 (enExample) |
| WO (1) | WO2014170319A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2116539A1 (en) | 2008-04-25 | 2009-11-11 | Laboratorios Del. Dr. Esteve, S.A. | 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof |
| EP2353598A1 (en) | 2010-02-04 | 2011-08-10 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for use in the prevention and/or treatment of postoperative pain |
| EP2353591A1 (en) | 2010-02-04 | 2011-08-10 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof |
| EP2388005A1 (en) | 2010-05-21 | 2011-11-23 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy |
| EP2415471A1 (en) | 2010-08-03 | 2012-02-08 | Laboratorios Del. Dr. Esteve, S.A. | Use of sigma ligands in opioid-induced hyperalgesia |
| EP2524694A1 (en) | 2011-05-19 | 2012-11-21 | Laboratorios Del. Dr. Esteve, S.A. | Use of sigma ligands in diabetes type-2 associated pain |
| SG11201604480PA (en) | 2013-12-17 | 2016-07-28 | Esteve Labor Dr | SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs) AND SIGMA RECEPTOR LIGANDS COMBINATIONS |
| US11034669B2 (en) | 2018-11-30 | 2021-06-15 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7666882B2 (en) * | 2002-11-15 | 2010-02-23 | E.I. Du Pont De Nemours And Company | Anthranilamide insecticides |
| AU2005276590B2 (en) | 2004-08-27 | 2011-05-19 | Laboratorios Del Dr. Esteve, S.A. | Sigma receptor inhibitors |
| US8889173B2 (en) * | 2008-04-18 | 2014-11-18 | Warsaw Orthopedic, Inc. | Alpha adrenergic receptor agonists for treatment of pain and/or inflammation |
| EP2116539A1 (en) * | 2008-04-25 | 2009-11-11 | Laboratorios Del. Dr. Esteve, S.A. | 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof |
| EP2429521B1 (en) * | 2009-05-15 | 2017-10-18 | Recro Pharma, Inc. | Sublingual dexmedetomidine compositions and methods of use thereof |
| EP2292236A1 (en) | 2009-08-14 | 2011-03-09 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for the prevention or treatment of pain induced by chemotherapy |
| HRP20161128T1 (hr) | 2009-11-25 | 2016-11-18 | Laboratorios Del Dr. Esteve, S.A. | Hidrokloridna sol 4-[2-[[5-metil-1-(2-naftalenil)-1h-pirazol-3-il]oksi]etil]morfolina |
| EP2335688A1 (en) | 2009-11-25 | 2011-06-22 | Laboratorios Del. Dr. Esteve, S.A. | Pharmaceutical compositions comprising sigma receptor ligands |
| PL2531177T3 (pl) | 2010-02-04 | 2016-11-30 | Chlorowodorek 4-[2-[[5-metylo-1-(2-naftalenylo)-1h-pirazol-3-ilo]oksy]etylo]morfoliny i solwaty | |
| US20110269727A1 (en) * | 2010-04-29 | 2011-11-03 | Toledano Annette C | Composition to reduce allodynic back pain and related method of use |
| EP2388005A1 (en) | 2010-05-21 | 2011-11-23 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy |
| EP2415471A1 (en) | 2010-08-03 | 2012-02-08 | Laboratorios Del. Dr. Esteve, S.A. | Use of sigma ligands in opioid-induced hyperalgesia |
| EP2426111A1 (en) | 2010-08-09 | 2012-03-07 | Laboratorios Del. Dr. Esteve, S.A. | 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride amorphous solid forms |
| EP2460519A1 (en) | 2010-12-03 | 2012-06-06 | Laboratorios Del. Dr. Esteve, S.A. | Use of sigma ligands in bone cancer pain |
| EP2524694A1 (en) * | 2011-05-19 | 2012-11-21 | Laboratorios Del. Dr. Esteve, S.A. | Use of sigma ligands in diabetes type-2 associated pain |
-
2013
- 2013-04-16 EP EP13382140.5A patent/EP2792352A1/en not_active Withdrawn
-
2014
- 2014-04-11 AR ARP140101577A patent/AR095858A1/es unknown
- 2014-04-15 BR BR112015026259A patent/BR112015026259A2/pt not_active Application Discontinuation
- 2014-04-15 RU RU2015148766A patent/RU2015148766A/ru not_active Application Discontinuation
- 2014-04-15 SG SG11201508102XA patent/SG11201508102XA/en unknown
- 2014-04-15 CN CN201480021541.0A patent/CN105228606A/zh active Pending
- 2014-04-15 HK HK16107566.1A patent/HK1219431A1/zh unknown
- 2014-04-15 JP JP2016508133A patent/JP2016516792A/ja active Pending
- 2014-04-15 EP EP14718049.1A patent/EP2986284A1/en not_active Withdrawn
- 2014-04-15 AU AU2014255837A patent/AU2014255837A1/en not_active Abandoned
- 2014-04-15 WO PCT/EP2014/057608 patent/WO2014170319A1/en not_active Ceased
- 2014-04-15 MX MX2015014441A patent/MX2015014441A/es unknown
- 2014-04-15 CA CA2908926A patent/CA2908926A1/en not_active Abandoned
- 2014-04-15 US US14/784,736 patent/US20160058771A1/en not_active Abandoned
- 2014-04-15 KR KR1020157032620A patent/KR20150143754A/ko not_active Withdrawn
-
2015
- 2015-09-29 TN TN2015000440A patent/TN2015000440A1/en unknown
- 2015-10-01 PH PH12015502282A patent/PH12015502282A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TN2015000440A1 (en) | 2017-01-03 |
| BR112015026259A2 (pt) | 2017-07-25 |
| US20160058771A1 (en) | 2016-03-03 |
| EP2792352A1 (en) | 2014-10-22 |
| MX2015014441A (es) | 2016-06-21 |
| RU2015148766A3 (enExample) | 2018-03-29 |
| AU2014255837A1 (en) | 2015-11-05 |
| EP2986284A1 (en) | 2016-02-24 |
| SG11201508102XA (en) | 2015-11-27 |
| JP2016516792A (ja) | 2016-06-09 |
| KR20150143754A (ko) | 2015-12-23 |
| CA2908926A1 (en) | 2014-10-23 |
| AR095858A1 (es) | 2015-11-18 |
| RU2015148766A (ru) | 2017-05-18 |
| CN105228606A (zh) | 2016-01-06 |
| HK1219431A1 (zh) | 2017-04-07 |
| WO2014170319A1 (en) | 2014-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12016500356A1 (en) | Nsaid and sigma receptor ligand combinations | |
| PH12015502282A1 (en) | Alpha-2 adrenoceptor and sigma receptor ligand combinations | |
| PH12016501095A1 (en) | Gabapentinoids and sigma receptor ligands combinations | |
| PH12021552333A1 (en) | Pharmaceutical composition of s-ketamine hydrocholoride | |
| PH12015502013B1 (en) | Pharmaceutical composition of s-ketamine hydrochloride | |
| NZ745556A (en) | Androgen receptor modulator and uses thereof | |
| DK201470535A (en) | Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof | |
| JO3452B1 (ar) | بنزاميدات أمينو اريل مغاير كمثبطات كيناز | |
| NZ732511A (en) | Small molecule inhibitors of egfr and pi3k | |
| NZ706990A (en) | A veterinary method of alleviating noise aversion | |
| SA515370011B1 (ar) | طرق لعلاج سرطان باستخدام علاج توليفي من مركب داي هيدرو بيرازينو-بيرازين | |
| MX344846B (es) | Combinacion de granulos cargados activos con activos adicionales. | |
| PH12016501096A1 (en) | SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs) AND SIGMA RECEPTOR LIGANDS COMBINATIONS | |
| MX2017006709A (es) | Agente para prevenir o mejorar sintomas causados por desequilibrio de las hormonas sexuales. | |
| PH12016501814A1 (en) | Inhibitors of the wnt signalling pathways | |
| PH12016501101A1 (en) | Veliparib in combination with carboplatin for the treatment of triple negative breast cancer | |
| MX2015013911A (es) | Combinacion sinergistica de paracetamol/celecoxib para el tratamiento de dolor inflamatorio. | |
| WO2014153505A3 (en) | Treatment of chemotherapy-induced peripheral neuropathy | |
| PH12015502703A1 (en) | Pharmaceutical compositions | |
| UA113065C2 (xx) | Композиція для нанесення на шкіру та її застосування | |
| PH12014000105A1 (en) | Therapeutic methods and compositions for treating diabetes utilizing diterpenoid compounds |